Company Profile
Esperion Therapeutics Stock Price, News & Analysis
- Ticker:
- ESPR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.18 USD (-0.31%)
Close
Last updated: July 10, 2026
808M USD
Market cap
Why the stock is moving
Current closing-price context is not available for ESPR.
Company overview
Oral Cardiometabolic Medicines
Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase.
Bempedoic Acid Franchise
NEXLETOL and NEXLIZET are once-daily, non-statin LDL-cholesterol-lowering medicines based on bempedoic acid. Esperion commercializes the products in the United States and works with partners across more than 40 countries.
Enbumyst Expansion
Esperion has agreed to acquire Corstasis Therapeutics and Enbumyst, an approved bumetanide nasal spray. The product would add a differentiated diuretic to its cardiovascular commercial portfolio.
Combination Development
The company is developing oral triple-combination regimens intended to deliver larger LDL-C reductions through complementary mechanisms. These products are designed to compete with other intensive lipid-lowering options while retaining oral administration.
Rare-Disease Pipeline
ESP-2001 is a wholly owned program for primary sclerosing cholangitis, a rare liver disease without approved treatment. Esperion is also applying its ACLY expertise to additional next-generation programs.
Future catalysts
Canadian approval decision for NEXLIZET expected in 2026.
Australian decisions on NEXLETOL and NEXLIZET expected in the fourth quarter of 2026.
Completion of clinical requirements and planned commercialization of oral triple-combination products in 2027.
Recent news
- 01
- 02
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Source: Esperion Therapeutics
- 03
- 04
Esperion to be Acquired by ARCHIMED
Source: Esperion Therapeutics
- 05
Esperion to Report First Quarter 2026 Financial Results on May 7
Source: Esperion Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Esperion Therapeutics (ESPR)?
Esperion Therapeutics (ESPR) most recently closed at 3.18 USD, a -0.31% move versus the previous session.
What is the market cap of Esperion Therapeutics (ESPR)?
Esperion Therapeutics currently has a market capitalization of 808M USD on BioPharmSignal.
What does Esperion Therapeutics do?
Oral Cardiometabolic Medicines Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase. Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin LDL-cholesterol-lowering medicines...
On which exchange is ESPR stock listed?
Esperion Therapeutics (ESPR) is associated with NASDAQ, United States, Biopharma.
What is LDL-C?
Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin LDL-cholesterol-lowering medicines based on bempedoic acid.
Which conditions is Esperion Therapeutics targeting with LDL-C?
Esperion Therapeutics is associated with cardiovascular disease, metabolic disease based on its company overview and current catalyst commentary.
How does Esperion Therapeutics describe recent progress with LDL-C?
Canadian approval decision for NEXLIZET expected in 2026. Australian decisions on NEXLETOL and NEXLIZET expected in the fourth quarter of 2026. Completion of clinical requirements and planned commercialization of oral triple-combination products in 2027.
What is ESP-2001?
Rare-Disease Pipeline ESP-2001 is a wholly owned program for primary sclerosing cholangitis, a rare liver disease without approved treatment.